Datasheet

Biological Description

Specificity	LAG3 Antibody [K23N22] detects endogenous levels of total LAG3 protein.
Background	LAG3 (Lymphocyte activation gene 3, CD223) is a type I transmembrane inhibitory receptor of the immunoglobulin superfamily that functions as an immune checkpoint, structurally related to CD4 but with distinct regulatory features. It is encoded on chromosome 12p13.32 in humans, producing a ~70 kDa protein composed of four extracellular Ig-like domains (D1–D4), a connecting peptide, a single transmembrane domain, and a short cytoplasmic tail containing three conserved motifs (a serine phosphorylation site, KIEELE, and EP repeats) that mediate inhibitory signaling. LAG3 is predominantly expressed on activated CD4⁺ and CD8⁺ T cells, regulatory T cells, natural killer (NK) cells, B cells, and plasmacytoid dendritic cells, with expression strongly upregulated upon chronic antigen stimulation, particularly in cancer and chronic infections. Functionally, LAG3 binds MHC class II with higher affinity than CD4 and also interacts with other ligands such as fibrinogen-like protein 1 (FGL1), galectin-3, LSECtin, and the TCR–CD3 complex, leading to suppression of T cell proliferation, cytokine secretion, calcium signaling, and effector functions. By dampening TCR signaling and promoting T cell exhaustion, LAG3 serves as a critical regulator of immune homeostasis and a key immune checkpoint in the tumor microenvironment, making it an important therapeutic target in cancer immunotherapy and autoimmunity.

Specificity

LAG3 Antibody [K23N22] detects endogenous levels of total LAG3 protein.

Background

LAG3 (Lymphocyte activation gene 3, CD223) is a type I transmembrane inhibitory receptor of the immunoglobulin superfamily that functions as an immune checkpoint, structurally related to CD4 but with distinct regulatory features. It is encoded on chromosome 12p13.32 in humans, producing a ~70 kDa protein composed of four extracellular Ig-like domains (D1–D4), a connecting peptide, a single transmembrane domain, and a short cytoplasmic tail containing three conserved motifs (a serine phosphorylation site, KIEELE, and EP repeats) that mediate inhibitory signaling. LAG3 is predominantly expressed on activated CD4⁺ and CD8⁺ T cells, regulatory T cells, natural killer (NK) cells, B cells, and plasmacytoid dendritic cells, with expression strongly upregulated upon chronic antigen stimulation, particularly in cancer and chronic infections. Functionally, LAG3 binds MHC class II with higher affinity than CD4 and also interacts with other ligands such as fibrinogen-like protein 1 (FGL1), galectin-3, LSECtin, and the TCR–CD3 complex, leading to suppression of T cell proliferation, cytokine secretion, calcium signaling, and effector functions. By dampening TCR signaling and promoting T cell exhaustion, LAG3 serves as a critical regulator of immune homeostasis and a key immune checkpoint in the tumor microenvironment, making it an important therapeutic target in cancer immunotherapy and autoimmunity.

Usage Information

Application

WB, IP, IHC, IF, FCM

Dilution

WB	IP	IHC	IF	FCM
1:500	1:30	1:1000	1:100	1:500

Reactivity

Human

Source

Rabbit Monoclonal Antibody

MW

54kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

Exprimental Methods

References

https://pubmed.ncbi.nlm.nih.gov/34067904/
https://pubmed.ncbi.nlm.nih.gov/38556085/

LAG3 Antibody [K23N22]

Biological Description

Usage Information

References

Application Data